MiNK Therapeutics, Inc. (INKT)
After hours:
| Previous close | 1.0100 |
| Open | 1.0300 |
| Bid | 0.9745 x 100 |
| Ask | 1.0400 x 100 |
| Day's range | 1.0000 - 1.0480 |
| 52-week range | 0.7500 - 3.3400 |
| Volume | |
| Avg. volume | 189,129 |
| Market cap | 35.075M |
| Beta (5Y monthly) | 0.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6500 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
- GuruFocus.com
MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...
Discover how MiNK Therapeutics Inc navigates financial challenges and advances key clinical programs amidst strategic operational adjustments.
GlobeNewswireMiNK Reports First Quarter 2024 Results
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, in
- GlobeNewswire
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
